Literature DB >> 25589515

Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis.

Tatjana Mallano1, Katrin Palumbo-Zerr1, Pawel Zerr1, Andreas Ramming1, Barbara Zeller1, Christian Beyer1, Clara Dees1, Jingang Huang1, Tsonwin Hai2, Oliver Distler3, Georg Schett1, Jörg H W Distler1.   

Abstract

BACKGROUND: Activating transcription factor 3 (ATF3), a member of the ATF/cAMP-responsive element binding (CREB) family of transcription factors, regulates cellular response to stress including oxidative stress. The aim of this study was to analyse the role of ATF3 in fibroblast activation in systemic sclerosis (SSc).
METHODS: ATF3 was analysed by reverse transcription quantitative PCR, western blot and immunohistochemistry. ATF3 knockout fibroblasts and mice were used to study the functional role of ATF3. Knockdown experiments, reporter assays and coimmunoprecipitation were performed to study the effects of ATF3 on Smad and activation protein 1 (AP-1) signalling. The role of c-Jun was analysed by costaining, specific inactivation and coimmunoprecipitation.
RESULTS: Transforming growth factor-β (TGFβ) upregulates the expression of ATF3 in SSc fibroblasts. ATF3-deficient fibroblasts were less sensitive to TGFβ, whereas ectopic expression of ATF3 enhanced the profibrotic effects of TGFβ. Mechanistically, ATF3 interacts with Smad3 directly on stimulation with TGFβ and regulates Smad activity in a c-Jun-dependent manner. Knockout of ATF3 protected mice from bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGFβ receptor I. Reporter assays and analyses of the expression of Smad target genes demonstrated that binding of ATF3 regulates the transcriptional activity of Smad3.
CONCLUSIONS: We demonstrate for the first time a key role for ATF3 in fibrosis. Knockout of the ATF3 gene reduced the stimulatory effect of TGFβ on fibroblasts by interfering with canonical Smad signalling and protected the mice from experimental fibrosis in two different models. ATF3 might thus be a candidate for molecular targeted therapies for SSc. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Fibroblasts; Systemic Sclerosis; Treatment

Mesh:

Substances:

Year:  2015        PMID: 25589515     DOI: 10.1136/annrheumdis-2014-206214

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Mouse Models of Skin Fibrosis.

Authors:  Aleix Rius Rigau; Markus Luber; Jörg H W Distler
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

3.  Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse Model.

Authors:  Ran Nagahara; Tomomitsu Matono; Takaaki Sugihara; Yukako Matsuki; Masafumi Yamane; Toshiaki Okamoto; Kenichi Miyoshi; Takakazu Nagahara; Jun-Ichi Okano; Masahiko Koda; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

4.  Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer.

Authors:  Nawab Azizi; Jelena Toma; Mickenzie Martin; Muhammad Faran Khalid; Fatemeh Mousavi; Phyo Wei Win; Maria Teresa Borrello; Nina Steele; Jiaqi Shi; Marina Pasca di Magliano; Christopher L Pin
Journal:  Oncogene       Date:  2021-04-16       Impact factor: 9.867

5.  ATF3 represses PINK1 gene transcription in lung epithelial cells to control mitochondrial homeostasis.

Authors:  Marta Bueno; Judith Brands; Lauren Voltz; Kaitlin Fiedler; Brenton Mays; Claudette St Croix; John Sembrat; Rama K Mallampalli; Mauricio Rojas; Ana L Mora
Journal:  Aging Cell       Date:  2018-01-24       Impact factor: 9.304

6.  Loss of the transcription factor RBPJ induces disease-promoting properties in brain pericytes.

Authors:  Rodrigo Diéguez-Hurtado; Katsuhiro Kato; Benedetto Daniele Giaimo; Melina Nieminen-Kelhä; Hendrik Arf; Francesca Ferrante; Marek Bartkuhn; Tobias Zimmermann; M Gabriele Bixel; Hanna M Eilken; Susanne Adams; Tilman Borggrefe; Peter Vajkoczy; Ralf H Adams
Journal:  Nat Commun       Date:  2019-06-27       Impact factor: 14.919

7.  Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches.

Authors:  Qiao Wang; Guoshan Shi; Yun Zhang; Feilong Lu; Duoli Xie; Chengping Wen; Lin Huang
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

8.  GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

Authors:  Katarina Zmajkovicova; Yasmina Bauer; Katalin Menyhart; Marie Schnoebelen; Diego Freti; Maxime Boucher; Bérengère Renault; Rolf Studer; Magdalena Birker-Robaczewska; Axel Klenk; Oliver Nayler; John Gatfield
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

Review 9.  The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration Pathology.

Authors:  Juha M T Hyttinen; Ram Kannan; Szabolcs Felszeghy; Minna Niittykoski; Antero Salminen; Kai Kaarniranta
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

10.  Activating transcription factor 3 (ATF3) regulates cell growth, apoptosis, invasion and collagen synthesis in keloid fibroblast through transforming growth factor beta (TGF-beta)/SMAD signaling pathway.

Authors:  Xue-Ming Wang; Xiu-Mei Liu; Yuting Wang; Zhen-Yu Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.